Login to Your Account

Pharma: clinic roundup

Friday, December 13, 2013
Mallinckrodt Inc., of St. Louis, said the Phase III trial of MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, met the primary efficacy endpoint of change in pain from baseline over 48 hours compared to placebo in managing moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription